Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomesESMO OPENIF8.32024-06-011OAAI
Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST RegistryEJSOIF2.92023-09-011OAAI
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry DataTARGETED ONCOLOGYIF42023-04-209OAAI
Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?ESMO OPENIF8.32022-12-018OAAI
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST PatientsTARGETED ONCOLOGYIF42022-11-145OAAI
Real-world data from patients with gastrointestinal stromal tumors (GIST) treated in Dutch GIST expertise centersANNALS OF ONCOLOGYIF65.42021-09-010OAAI
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European studyEJSOIF2.92021-08-016OAAI
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenibEXPERT OPINION ON INVESTIGATIONAL DRUGSIF4.12020-12-0320OAAI
Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohortEJSOIF2.92020-06-0129OAAI
The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitusEUROPEAN JOURNAL OF INTERNAL MEDICINEIF6.12009-05-0162PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向